Statinlerin Toksikolojik Açıdan Değerlendirilmesi

Year 2017, Issue: 1, 18 - 28, 01.01.2017

Tuğçe Çetin Hilal Özgüneş

Abstract

Hipolipidemikler veya halk arasında bilinen adıyla kolesterol düşürücü ilaçlar, hiperlipidemi tedavisinde kullanılan ilaçların genel adıdır. Kalp damar hastalıklarının önlenmesi ve tedavisinde yaygın olarak kullanılmaktadırlar. Hipolipidemik ilaçlar, etki mekanizmalarına göre farklı sınıflara ayrılırlar. Bunlardan en çok bilineni ve en önemlisi statinlerdir. Uzun süreli statin kullanımı kişide kas toksisitesine veya nadir fakat ciddi bir yan etki olan rabdomiyolize neden olabilir. Sitokrom P450 enzim sistemi ile metabolize olan statinler; aynı mekanizma ile metabolize olan birçok ilaç grubu ile etkileşirler. Simvastatin, lovastatin veya atorvastatin kullanan kişilerin greyfurt suyundan kaçınmaları veya azaltmaları gerekmektedir. Bu derlemede, statinlerin etki mekanizmaları, farmakokinetikleri, ilaç etkileşimleri ve yan etkileri ile ilgili bilgiler verilecektir.

Keywords

Hipolipidemikler, greyfurt suyu, statinler, yan etkiler, etkileşimler

Toxicological Evaluation of Statins

Abstract

Hypolipidemics, in other words cholesterol lowering drugs, are the general names of the drugs which are used in hyperlipidemia treatment. They are widely used in the treatment and prevention of atherosclerotic disease. Hypolipidemic drugs are classified in different groups according to their mode of actions. The most known and important one of these are statins. Long term use of statins can cause muscle toxicity or rhabdomyolysis which is a rare but serious side effect. Statins, which are metabolized by cytochrome P450 enzyme system, interact with many groups of medicine which metabolized by the same mechanism. Grapefruit juice consumption should be avoided or limited when one is taking simvastatin, lovastatin or atorvastatin. In this rewiev, mechanism of action, pharmacokinetics, side effects and drug interactions of statins are reviewed.

Keywords

Hypolipidemics, grapefruit juice, statins, side effects, interactions

References

• Kayaalp SO: Akılcı Tedavi Yönünden Tıbbi Farmakoloji 1. Cilt. Pelikan Yayıncılık; Ankara, Türkiye, 2012.
• Lu Y, Cheng Z, Zhao Y, Chang X, Chan C, Bai Y, Cheng N: Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. Atherosclerosis 2016, 254:215-227.
• Oktay Ş. Hipolipidemik İlaçlar. In: Dökmeci İ (eds), İlaç Uygulamalarında Temel Kavramlar. Nobel Tıp Kitabevleri; İstanbul, Türkiye. 1992: pp 276-284.
• Kayaalp SO: Rasyonel Tedavi Yönünden Tıbbi Farmakoloji Cilt 2. Feryal Matbaacılık; Ankara, Türkiye,1990.
• Kayaalp SO: Tıbbi Farmakoloji Gözden Geçirme Kitabı. Hacettepe Taş Kitabevi; Ankara, Türkiye,1995.
• Ferah I, Avşar Ü, Albayrak A: Statinler söylenildiği gibi güvenilir ilaçlar mıdır? Endikasyon ve risk açısından statinler. Journal of Clinical and Analytical Medicine 2014, 5(4):341-346.
• Türkiye Endokrinoloji ve Metabolizma Derneği: Lipit Metabolizma Bozuklukları Tanı ve Tedavi Kılavuzu. Pelin Ofset Matbaacılık; Ankara, Türkiye, 2015.
• Lim B, McCormack R, O’Loughlin C, Ramphul M, Sehmer B: Statins: A review of benefits and risks. Trinity Student Medical Journal 2007, 14(8):52-56.
• Ertaş FS: Yaşam Boyu Tedavi Perspektifinde Statinler. Türk Kardiyoloji Derneği Arşivi 2009, 37(2):29-36.
• Sikora J, Kostka B, Marczyk I, Krajewska U, Chałubiński M, Broncel M: Effect of statins on platelet function in patients with hyperlipidemia. Archives of Medical Science 2013, 9(4):622-628.
• Abacıoğlu N, Onursal E, Hatunoğlu K, Abacıoğlu H: Türkiye Tıbbi İlaç Rehberi Güncel Farmalist. Palme Yayıncılık; Ankara Türkiye, 2010.
• García MJ, Reinoso RF, Sánchez Navarro A, Prous JR: Clinical pharmacokinetics of statins. Methods and Findings in Experimental and Clinical Pharmacology 2003, 25(6):457-481.
• Plakogiannis R, Cohen H: Optimal low-density lipoprotein cholesterol lowering-morning versus evening statin administration. Annals of Pharmacotherapy 2007, 41(1):106-110.
• Causevic-Ramosevac A, Semiz S: Drug interactions with statins. The Journal of Croatian Pharmaceutical Society 2013, 63(3):277-293
• Golomb BA, Evans MA: Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism. American Journal of Medicine 2008, 8(6):373-418.
• JR Gillet RC, Clark R, Norrell A: Considerations for Safe Use of Statins: Liver Enzyme Abnormalities and Muscle Toxicity. American Family Physician 2011, 83(6):711-716.
• Thompson PD, Panza G, Zaleski A, Taylor B: Statin-Associated Side Effects. Journal of the American College of Cardiology 2016, 67(20):2395-2410.
• Saxon DR, Eckel RH: Statin Intolerance: A Literature Review and Management Strategies. Progress in cardiovascular diseases 2016, 59(2):153-164.
• Samaras K, Brodaty H, Sachdev PS: Does statin use cause memory decline in the elderly?. Trends in cardiovascular medicine 2016, 26(6):550-565.
• Rojas-Fernandez C, Hudani Z, Bittner V: Statins and cognitive side effects: what cardiologists need to know. Cardiology clinics 2015, 33(2):245-256.
• Tunca M: Yaşlılarda İlaç Etkileşimleri ve Klinik Önemi. Turkish Journal of Geriatrics 2006, 9(özel sayı):45-48.
• Goh IX, How CH, Tavintharan S: Cytochrome P450 drug interactions with statin therapy. Singapore Medical Journal 2013, 54(3):131-135
• Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clinical Pharmacology & Therapeutics 2006, 80(6):565-581.
• Moßhammer D, Mörike K, Schaeffeler E, Schwab M: Mechanisms and assessment of statin-related muscular adverse effects. British Journal of Clinical Pharmacology 2014, 78(3):454-466.
• Süzer Ö, Neşetoğlu R, Baruksal G, Dedeoğlu BD: İlaç Grupları ve İlaçlar İçin İlaç Etkileşim Örnekleri. Klinik Gelişim Dergisi 2008, 21(2):46-67.
• Neuvonen PJ, Kantola T, Kivistö KT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clinical Pharmacology & Therapeutics 1998, 63(3):332-341.
• Kırılmaz B: Yaşlılarda Kardiyovasküler İlaçların Etkileşimi ve Yan etkileri. Turkish Journal of Geriatrics 2010, 13(özel sayı):107-113.
• Bushra R, Aslam N, Khan AY: Food-Drug Interactions. Oman Medical Journal 2011, 26(2):77-83.
• Genser D: Food and Drug Interaction: Consequences for the Nutrition/Health Status. Annals of Nutrition&Metabolism 2008, 52(1):29-32.
• Kiani J, Imam SZ: Medicinal Importance of Grapefruit Juice and Its Interaction with Various Drugs. Nutrition Journal 2007, 33(6):1-9.
• Bailey DG, Dresser G, Arnold MO: Grapefruit-Medication Interactions: Forbidden Fruit or Avoidable Consequences. Canadian Medical Association Journal 2012, 185(6):507-514.
• Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R: Incidence of hospitalized rhabdomyolysis in patients treated with lipid- lowering drugs. The Journal of the American Medical Association 2004, 292(21):2585-2590.
• İşçi AZ, Aktaş G, Karaçay S, Şavlı H: Statin ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomiyoliz: Bir Olgu Nedeniyle. Abant Medical Journal 2013, 2(2):171-172.
• Backes J, Gibson CA, Howard PA: Optimal lipid modification: the rationale for combination therapy. Oxford Journals 2005, 1(4):317-331.
• Borrelli F, Izzo AA: Herb–Drug Interactions with St John’s Wort (Hypericum perforatum):an Update on Clinical Observations. The American Association of Pharmaceutical Scientists Journal 2009, 11(4):721.
• Varel M. Hypericum perforatum (Sarı kantaron). In: Demirezer LÖ (eds), FFD Monografları Tedavide Kullanılan Bitkiler [Elektronik Sürüm]. Akademisyen Kitabevi; Ankara, Türkiye. 2011.
• Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang Y, Hennessy S: Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding Risk. American Journal of Medicine 2011, 123(2):1-14.
• Lennernäs H: Clinical pharmacokinetics of atorvastatin. Clinical pharmacokinetics 2003, 42(13):1141-1160.
• Kazmin A, Garcia-Bournissen F, Koren G: Risks of statin use during pregnancy: a systematic review. Journal of obstetrics and gynaecology Canada 2007, 29(11):906-908.
• Karalis DG, Hill AN, Clifton S, Wild RA: The risk of statin use in pregnancy: A systematic review. Journal of Clinical Lipidology 2016, 10(5):1081-1090.
• Henck JW, Craft WR, Black A, Colgin J, Anderson JA: Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. Toxicological Sciences 1998, 41(1):88-99.